Compare Immunovant Inc. Common Stock (IMVT) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Nuscale Power Corporation — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Nuscale Power Corporation trades at $7.45 (market cap $3.15B). The key difference: Immunovant Inc. Common Stock is far larger — about 2.1× Nuscale Power Corporation's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Nuscale Power Corporation for 29 Days on average.
| IMVT | SMR | |
|---|---|---|
Market Cap | $6.62B | $3.15B |
Volume | 1,131,364 | 38,437,205 |
Sector | Health | Industrials |
52-Week High | $44.96 | $53.43 |
52-Week Low | $17.03 | $7.32 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $5.72B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NuScale Power (SMR) trades at $7.67, down 4.42% today, amid bearish technical signals and negative profitability metrics. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with analyst consensus showing a mixed 50% buy rating but a $11.25 price target. Recent news highlights ongoing legal investigations and competitive pressures in the nuclear energy sector.
The outlook remains challenging with significant operational losses and cash burn, though analyst targets suggest potential upside. Key risks include execution on commercialization, dilution concerns, and intense SMR competition. The stock's future hinges on converting its $1.1 billion cash position into revenue-generating projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
